Life-threatening serotonin syndrome in a patient with chronic heart failure and CYP2D6*1/*5

Mayo Clinic Proceedings

Volumn 79, Issue 11, 2004, Pages 1444-1448

  Sato, Akinori ^a   Okura, Yuji ^a   Minagawa, Shiroh ^a   Ohno, Yukiko ^a   Fujita, Satoru ^a   Kondo, Daisuke ^a   Hayashi, Manabu ^a   Komura, Satoru ^a   Kato, Kiminori ^a   Hanawa, Haruo ^a   Kodama, Makoto ^a   Aizawa, Yoshifusa ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIGOXIN; DISOPYRAMIDE PHOSPHATE; FUROSEMIDE; METOPROLOL; OMEPRAZOLE; PAROXETINE; SPIRONOLACTONE; TICLOPIDINE; VALSARTAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; ATAXIA; BEHAVIOR THERAPY; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG METABOLISM; ELECTROCARDIOGRAPHY; FEVER; GENETIC SCREENING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE BIOPSY; HEARTBURN; HEMOFILTRATION; HUMAN; HYPERREFLEXIA; LIVER FAILURE; MALE; MYOCLONUS; NAUSEA; PANIC; RESTLESSNESS; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SHIVERING;

EID: 7544245270     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.11.1444     Document Type: Article

References (23)

1. Insel TR, Roy BF, Cohen RM, Murphy DL. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982;139:954-955.
2. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79:201-209.
3. Jaunay E, Gaillac V, Guelfi JD. Serotonin syndrome: which treatment and when? [in French]. Presse Med. 2001;30:1695-1700.
4. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-109.
5. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218-224.
6. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325:1332-1333.
7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
8. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54:227-240.
9. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149:1785-1789.
10. Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival [published correction appears in JAMA. 1994;271:1082]. JAMA. 1993;270:1819-1825.
11. Berkman LF, Blumenthal J, Burg M, et al, Enhancing Recovery in Coronary Heart Disease Patients Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106-3116.
12. Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry. 2003;54:262-268.
13. Stalh SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge, Mass: Cambridge University Press; 2000:135-198.
14. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am. 2000;18:317-325.
15. Mills KC. Serotonin syndrome: a clinical update. Crit Care Clin. 1997;13:763-783.
16. Sarko J. Antidepressants, old and new: a review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am. 2000;18:637-654.
17. Oates JA, Roden DM, Wilkinson GR. Principles of drug therapy. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. Vol 1. 15th ed. New York, NY: McGraw-Hill; 2001:419-430.
18. Benbow SJ. Gill G. Paroxetine and hepatotoxicity. BMJ. 1997;314:1387.
19. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474-485.
20. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol. 2003;17:27-41.
21. Kubota T, Yamaura Y, Ohkawa N, Kara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50:31-34.
22. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8:15-26.
23. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997;62:334-347.